AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Cohere Health®, a recognized leader in clinical intelligence, announces Cohere Connecttm, offering health plans the tools and support to meet and exceed the prior authorization (PA) compliance ...

Cohere Health®, a recognized leader in clinical intelligence, announces Cohere Connect™, offering health plans the tools and support to meet and exceed the prior authorization (PA) compliance mandates ...